Remogliflozin Etabonate is an SGLT2 inhibitor used to treat type 2 diabetes. It works by promoting the excretion of glucose through urine, thereby lowering blood sugar levels. Remogliflozin Etabonate is effective in managing diabetes and reducing cardiovascular risks. In summary, Remogliflozin Etabonate is vital for diabetes management.
Remogliflozin Etabonate inhibits SGLT2, reducing glucose reabsorption in the kidneys and increasing urinary glucose excretion.



